Vanguard Group’s Dimension Therapeutics, Inc DMTX Stock Holding History

Vanguard Group’s Portfolio DMTX Stock Details DMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-610,285	Closed	-$3.66M	–	4165
2017 Q3	$3.66M	Buy	610,285 +96,341	+19%	+$250K	﹤0.01%	3226
2017 Q2	$745K	Sell	513,944 -156,948	-23%	-$213K	﹤0.01%	3644
2017 Q1	$1.17M	Buy	670,892 +23,263	+4%	+$61.7K	﹤0.01%	3537
2016 Q4	$2.82M	Sell	647,629 -25,054	-4%	-$133K	﹤0.01%	3244
2016 Q3	$5.37M	Buy	672,683 +246,518	+58%	+$1.78M	﹤0.01%	2964
2016 Q2	$2.56M	Buy	426,165 +348,311	+447%	+$2.65M	﹤0.01%	3281
2016 Q1	$610K	Buy	77,854 +51,388	+194%	+$405K	﹤0.01%	3739
2015 Q4	$298K	Buy	+26,466	New	+$335K	﹤0.01%	3943

Vanguard Group's DMTX Position: Q4 2017 in Review

Vanguard Group sold out of Dimension Therapeutics, Inc (DMTX) in Q4 2017, closing a stake of 610,285 shares — an estimated $3.66M sold.

Vanguard Group first reported a position in DMTX in Q4 2015 and held it in 8 quarters. The position peaked at $5.37M in Q3 2016. 0 funds tracked by Wall St. Rank hold DMTX as of Q4 2017.

Vanguard Group reported no remaining Dimension Therapeutics, Inc position as of Q4 2017 after selling out during the quarter.
Vanguard Group sold 610,285 Dimension Therapeutics, Inc shares in Q4 2017, an estimated $3.66M.
Vanguard Group first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 8 quarters.
Vanguard Group's Dimension Therapeutics, Inc position peaked at $5.37M in Q3 2016.
0 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q4 2017.

Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.